Prävention der KHK durch Pravastatin bei Männern mit Hypercholesterinämie

Munchener Medizinische Wochenschrift

Volumn 138, Issue 3, 1996, Pages 21-28

  Shepherd, J ^a   Cobbe, S M ^a   Ford, I ^a   Isles, C G ^b   Ross Lorimer, A ^a   Macfarlane, P W ^a   McKillop, J H ^a   Packard, C J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1842482919     PISSN: 03413098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Commitee of Principal Investigators. Brit. Heart J. 40 (1978) 1069-1118.
2. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. J. Amer. med. Ass. 251 (1984) 351-364.
3. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J. Amer. med. Ass. 251 (1984) 365-374.
4. Frick, M. H., Elo, O., Haapa, K. et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl. J. Med. 317 (1987) 1237-1245.
5. Oliver, M. F.: Might treatment of hypercholesterol-aemia increase non-cardiac mortality? Lancet 337 (1991) 1529-1531.
6. Hulley, S. B., Walsh, J. M. B., Newman, T. B.: Health policy on blood cholesterol: time to change directions. Circulation 86 (1992) 1026-1029.
7. Davey Smith, Q., Pekkanen, J.: Should there be a moratorium on the use of cholesterol lowering drugs? Brit. med. J. 304 (1992) 431-434.
8. LaRosa, J. C., Hunninghake, D., Bush, D. et al.: The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation 81 (1990) 1721-1733.
9. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Lancet 344 (1994) 1383-1389.
10. MAAS Investigators: Effect of Simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344 (1994) 633-638. [Erratum, Lancet 344 (1994) 762].
11. Furberg, C. D., Adams, H. P. Jr. Applegate, W. B. et al.: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 90 (1994) 1679-1687.
12. Jukema, J. W., Bruschke, A. V. G., van Boven, A. J. et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to, moderately elevated serum cholesterol levels: the Regression Growth Evaluation, Statin Study (REGRESS). Circulation 91 (1995) 2528-2540.
13. Grouse, J. R. III, Byington, R. P., Bond, M. G. et al.: Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Amer. J. Cardiol. 75 (1995) 455-459. [Erratum, Amer. J. Cardiol 75 (1995) 862],
14. Pitt, B., Mancini, G. B. J., Ellis, S. G. Rosman, H. S. Park, J-S.P., McGovern, M. E.: Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I): reduction in atherosclerosis progression and clinical events. J. Amer. Coll. Cardiol (In press).
15. The Pravastatin Multinational Study Group for Cardiac Risk Patients: Effects of pravastatin in patients with serum total cholesterol levels from 5,2 to 7,8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Amer. J. Cardiol. 72 (1993) 1031-1037.
16. West of Scotland Coronary Prevention Study Group: A coronary primary prevention study of Scottish men age 45-64 years: trial design. J. clin. Epidemiol. 45 (1992) 849-860.
17. EAS Task Force for Prevention of Coronary Heart Disease: Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr. Metab. Cardiovasc. Dis. 2 (1992) 113-156.
18. Prineas, R. J., Crow, R. S., Blackburn, H: The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. John Wright, PSG, Boston, 1982.
19. Lipid Research Clinics manual of laboratory operations, 1975, Washington, D. C.: Government Printing Office. 1975 (DREW publicaton no. NIH 85-268).
20. Crow, R. S., Prineas, R. J., Jacobs, D. R. Jr., Blackburn, H.: A new epidemiologic classification system for interim myocardial infarction from serial electrocardiographic changes. Amer. J. Cardiol. 64 (1969) 454-461.
21. Macfarlane, P. W., Devine, B., Latif, S., McLaughlin, S., Shoat, D. B., Watts, M. P.: Methodology of ECO interpretation in the Glasgow program, Methods Inf. Med. 29 (1990) 354-361.
22. Macfarlane, P. W., Latif, S., Shoat, D. S., Cobbe, S. M.: Automated serial ECG comparison using the Minnesota Code. Eur. Heart J. 11/Suppl. (1990) 411 (abstract).
23. West of Scotland Coronary Prevention Study Group: Computerised record linkage: compared with traditional follow-up methods in clinical trials and illustrated in a prospective epidemiologic study. J. clin. Epidemiol. (in press).
24. Collett, D.: Modelling survival data in medical research. Chapman & Hall. London 1994.
25. O'Brien, P. C., Fleming, T. Ft.: A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556.
26. West of Scotland Coronary Prevention Study Group: Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Amer. J. Cardiol. 76 (1995) 485-491.
27. Mann, J. I., Lewis, B., Shepherd, J. et al.: Blood lipid concentrations and other cardiovascular risk factors: distribution, prevalence, and detection in Britain. Brit. med. J. 296 (1988) 1702-1706.
28. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel II). J. Amer. med. Ass. 269 (1993) 3015-3023.
29. Jones, P. H., Farmer, J. A., Cressman, M. D. et al.: Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin. Cardiol. 14 (1991) 146-151.
30. Medical Research Council Working Party: MCR trial of treatment of mild hypertension principal results. Brit. med. J. 291 (1985) 97-104.
31. Miall, W. E., Greenberg, G.: Mild hypertension: is there pressure to treat? An account of the MRC trial. Cambridge University Press, Cambridge/United Kingdom 1987.